VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 30, 2013) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company has received purchase orders for Verisante Aura™ from the Company's exclusive distributors in Canada and Europe.
"This is a significant achievement for our Company as we take this ground-breaking technology to full commercialization," said Thomas Braun, President & CEO of Verisante. "The Company has been working very closely with our distribution partners on a strategic product launch. With manufacturing of Aura™ now underway and the full support of our distributors, 2013 is already shaping up to be a very successful year for our Company."
Verisante anticipates it will begin shipping Aura™ devices in February and will update the new Aura™ website with a list of clinics where patients can go to request an AuraScan™ when installations have been completed. Future reports of revenues and sales can be expected on a quarterly basis along with the reporting of our financial statements.
"Aura™ has the potential to revolutionize the way skin cancer is diagnosed," said Dan Webb, CEO of Clarion, exclusive Canadian distributor. "Clarion is committed to bringing this life-saving technology to medical professionals across Canada."
Dr. Barry Lycka, MD, a board-certified dermatologist and founder of the Canadian Skin Cancer Foundation, sees Aura™ becoming an integral part of the practice of any dermatologist who is diagnosing and treating skin cancer. "With the incidence of skin cancers on the rise and very few tools available to dermatologists to assist in the biopsy decision, I very much welcome a device such as Aura™," said Dr. Lycka, who practises in Edmonton (Alberta). "Clinical study results have shown that the device is fast, accurate and effective in improving patient outcomes."
In Europe, Michael Landsberg, President of Laserwelt, is excited to have the first Aura™ device available to German-speaking countries. "With the exclusive distribution rights for Aura™ in Germany, Austria and Liechtenstein, Laserwelt is ready to begin our sales and marketing efforts to the region's over 10,000 dermatologists and skin care specialists," said Landsberg. "The German market is highly scientific and sophisticated, and it can be a difficult market for new technologies to penetrate. However, with our depth of industry contacts and network of key opinion leaders in world-renowned University clinics, Laserwelt is in a unique position to bring these decisions makers together and introduce them to Aura's™ strong clinical study results, which we are confident will amount to significant sales."
And Dr. Henk-Peter Oonk, CEO of bo pharma BV is confident that Aura™ will be very well received in the Benelux region, where traditionally new technologies are adopted quickly. "Recent expansion of our exclusive distribution agreement for Aura™ to include the Nordic countries in addition to the Benelux region underlines our confidence in this product and this technology as we prepare for product launch."
Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura™ is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.
For information about purchasing an Aura™ in Canada, contact Clarion Medical Technologies at: email@example.com
For information about purchasing Aura™ in Germany, contact Laserwelt at: firstname.lastname@example.org
For information about purchasing Aura™ in Belgium, the Netherlands, Luxembourg, Sweden, Norway, Denmark, Finland or Iceland, contact bo pharma at: email@example.com
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.
Verisante Aura™ was awarded Popular Science Magazine's "Best of What's New Award" for 2011, and Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.